Chapter 24 – Cancer Systems Biology: A Robustness-Based Approach

[1]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[2]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[3]  Mattias Höglund,et al.  Power law distribution of chromosome aberrations in cancer. , 2003, Cancer research.

[4]  Helen M Byrne,et al.  Mathematical modelling of the use of macrophages as vehicles for drug delivery to hypoxic tumour sites. , 2004, Journal of theoretical biology.

[5]  S. Pongor,et al.  Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example. , 2004, Physical review. E, Statistical, nonlinear, and soft matter physics.

[6]  Y. Takahashi,et al.  Survival without tumor shrinkage: re-evaluation of survival gain by cytostatic effect of chemotherapy. , 1995, Journal of the National Cancer Institute.

[7]  S. Lindquist,et al.  Hsp90 as a capacitor for morphological evolution , 1998, Nature.

[8]  Hiroaki Kitano,et al.  Self-Extending Symbiosis: A Mechanism for Increasing Robustness Through Evolution , 2006 .

[9]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[10]  H. Skipper,et al.  A quick reference chart on cross resistance between anticancer patients. , 1972, Cancer chemotherapy reports.

[11]  Kazuyuki Aihara,et al.  A nonlinear model with competition between prostate tumor cells and its application to intermittent androgen suppression therapy of prostate cancer. , 2008, Mathematical biosciences.

[12]  Kathy Chen,et al.  Network dynamics and cell physiology , 2001, Nature Reviews Molecular Cell Biology.

[13]  R. Scheuermann,et al.  Cancer dormancy: Opportunities for new therapeutic approaches , 1997, Nature Medicine.

[14]  Erik Brynjolfsson,et al.  Consumer Surplus in the Digital Economy: Estimating the Value of Increased Product Variety at Online Booksellers , 2003, Manag. Sci..

[15]  Adam P. Arkin,et al.  Theoretical Design of a Gene Therapy To Prevent AIDS but Not Human Immunodeficiency Virus Type 1 Infection , 2003, Journal of Virology.

[16]  H. Kitano.  Cancer as a robust system: implications for anticancer therapy , 2004, Nature Reviews Cancer.

[17]  J. Doyle,et al.  Robustness as a measure of plausibility in models of biochemical networks. , 2002, Journal of theoretical biology.

[18]  J. Tischfield,et al.  Somatic recombination redux , 2003, Nature Genetics.

[19]  D. Rasnick.  Aneuploidy theory explains tumor formation, the absence of immune surveillance, and the failure of chemotherapy. , 2002, Cancer genetics and cytogenetics.

[20]  A. Hochhaus.  Cytogenetic and molecular mechanisms of resistance to imatinib. , 2003, Seminars in hematology.

[21]  J. Crowe,et al.  Preservation of mammalian cells—learning nature's tricks , 2000, Nature Biotechnology.

[22]  R. Hruban,et al.  Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. , 2000, Cancer research.

[23]  J. Doyle,et al.  Reverse Engineering of Biological Complexity , 2002, Science.

[24]  G. Odell,et al.  The segment polarity network is a robust developmental module , 2000, Nature.

[25]  W. Cannon.  The Wisdom of the Body , 1932 .

[26]  Katherine C. Chen,et al.  Integrative analysis of cell cycle control in budding yeast. , 2004, Molecular biology of the cell.

[27]  M. Gleave,et al.  Intermittent Androgen Suppression for Prostate Cancer: Rationale and Clinical Experience , 1998, European Urology.

[28]  A. Andrén-sandberg,et al.  Cytogenetic analysis of pancreatic carcinomas: Intratumor heterogeneity and nonrandom pattern of chromosome aberrations , 1998, Genes, chromosomes & cancer.

[29]  A. Vignery.  Macrophage fusion: are somatic and cancer cells possible partners? , 2005, Trends in cell biology.

[30]  R. Solé,et al.  Metapopulation dynamics and spatial heterogeneity in cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Radisky,et al.  Putting Tumors in Context , 2010 .

[32]  A. Bergman,et al.  Waddington's canalization revisited: Developmental stability and evolution , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Andrey Rzhetsky,et al.  Quantitative systems-level determinants of human genes targeted by successful drugs. , 2008, Genome research.

[34]  T. Tsuruo,et al.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.

[35]  P. Duesberg,et al.  Aneuploidy vs. gene mutation hypothesis of cancer: recent study claims mutation but is found to support aneuploidy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Odell,et al.  Robustness, Flexibility, and the Role of Lateral Inhibition in the Neurogenic Network , 2002, Current Biology.

[37]  H. Kitano,et al.  In Vivo Robustness Analysis of Cell Division Cycle Genes in Saccharomyces cerevisiae , 2006, PLoS genetics.

[38]  J. Doyle,et al.  Robust perfect adaptation in bacterial chemotaxis through integral feedback control. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  U. Alon,et al.  Robustness in bacterial chemotaxis , 2022 .

[40]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[41]  F T Bosman,et al.  Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma , 2001, International journal of cancer.

[42]  S. Rutherford,et al.  Between genotype and phenotype: protein chaperones and evolvability , 2003, Nature Reviews Genetics.

[43]  M. Heřmánková,et al.  A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Gleave,et al.  Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model. , 1997, The Journal of urology.

[45]  H. Herweijer,et al.  Multidrug resistance (mdr) genes in human cancer. , 1991, British Journal of Cancer.

[46]  A. Andrén-sandberg,et al.  Extensive cytogenetic heterogeneity in a benign retroperitoneal schwannoma. , 2001, Cancer genetics and cytogenetics.

[47]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[48]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[49]  J. Platt,et al.  Biological implications of cell fusion , 2005, Nature Reviews Molecular Cell Biology.

[50]  Ricard V. Solé,et al.  Phase transitions in unstable cancer cell populations , 2003 .

[51]  J. Ferrell.  Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability. , 2002, Current opinion in cell biology.

[52]  A. Chakraborty,et al.  Co-opting macrophage traits in cancer progression: a consequence of tumor cell fusion? , 2006, Contributions to microbiology.

[53]  H. Kitano.  A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.

[54]  John Doyle,et al.  Complexity and robustness , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[55]  S. Lindquist,et al.  Hsp90 as a capacitor of phenotypic variation , 2002, Nature.

[56]  Hiroaki Kitano,et al.  Biological robustness , 2008, Nature Reviews Genetics.

[57]  J M Carlson,et al.  Highly optimized tolerance: a mechanism for power laws in designed systems. , 1999, Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics.

[58]  S. Leibler,et al.  Robustness in simple biochemical networks , 1997, Nature.

[59]  C. Barthe,et al.  Roots of clinical resistance to STI-571 cancer therapy. , 2001, Science.

[60]  N. Barkai,et al.  Robustness of the BMP morphogen gradient in Drosophila embryonic patterning , 2022 .

[61]  D. Thieffry,et al.  Modularity in development and evolution. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[62]  M. Gleave,et al.  Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. , 2000, Molecular urology.

[63]  Hiroaki Kitano,et al.  Structure of Protein Interaction Networks and Their Implications on Drug Design , 2009, PLoS Comput. Biol..

[64]  C. Waddington,et al.  The strategy of the genes , 1957 .

[65]  Myriam Bernaudin,et al.  HIF1 and oxygen sensing in the brain , 2004, Nature Reviews Neuroscience.

[66]  Hiroaki Kitano,et al.  Violations of robustness trade-offs , 2010, Molecular systems biology.